Biotech Values

[vinmantoo]

Revance last quarter generated $51 million in revenue while spending a gaap $104 million is expense whlie EOLS generated $59 mil in revenue while incurring gaap $68 million in expenses.

I've been told by this board that it doesn't matter, well evidently it does.

EOLS had their toxin approved in 2019 so it is unfair to compare expenses to RVNC, whose toxin has been on the market for a much shorter time, meaning RVNC is spending money to start to generate sales.

I am not sure who is telling you expenses don't matter. Many here have been complaining that RVNC needs to cut costs.